Abstract:Tuberculosis (TB) is caused by infection with the bacterial pathogen Mycobacterium tuberculosis (M.tb) in the respiratory tract. There was an estimated 10.6 million people newly diagnosed with TB, and there were approximately 1.3 million deaths caused by TB in 2022. Although the global prevalence of TB has remained high for decades and is an annual leading cause of death attributed to infectious diseases, only one vaccine, Bacillus Calmette-Guérin (BCG), has been approved so far to prevent/attenuate TB disease. Correlates of protection or immunological mechanisms that are needed to control M.tb remain unknown. The protective role of antibodies after BCG vaccination has also remained largely unclear; however, recent studies have provided evidence for their involvement in protection against disease, as biomarkers for the state of infection, and as potential predictors of outcomes. Interestingly, the antibodies generated post-vaccination with BCG are linked to the activation of innate immune cascades, providing further evidence that antibody effector functions are critical for protection against respiratory pathogens such as M.tb. In this review, we aim to provide current knowledge of antibody application in TB diagnosis, prevention, and treatment. Particularly, this review will focus on 1) The role of antibodies in preventing M.tb infections through preventing Mtb adherence to epithelium, antibody-mediated phagocytosis, and antibody-mediated cellular cytotoxicity; 2) The M.tb-directed antibody response generated after vaccination and how humoral profiles with different glycosylation patterns of these antibodies are linked with protection against the disease state; and 3) How antibody-mediated immunity against M.tb can be further explored as early diagnosis biomarkers and different detection methods to combat the global M.tb burden. Broadening the paradigm of differentiated antibody profiling and antibody-based detection during TB disease progression offers new directions for diagnosis, treatment, and preventative strategies. This approach involves linking the aforementioned humoral responses with the disease state, progression, and clearance.

Mucosal Therapy of Multi-Drug Resistant Tuberculosis With IgA and Interferon-γ

Single-Dose Mucosal Immunotherapy with Chimpanzee Adenovirus-Based Vaccine Accelerates Tuberculosis Disease Control and Limits Its Rebound after Antibiotic Cessation

Airway Macrophages Mediate Mucosal Vaccine-Induced Trained Innate Immunity against Mycobacterium tuberculosis in Early Stages of Infection.

Immunotherapy Using IL-2 and GM-CSF is a Potential Treatment for Multidrug-Resistant Mycobacterium Tuberculosis

Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis.

Phosphoantigen/IL2 Expansion and Differentiation of Vγ2Vδ2 T Cells Increase Resistance to Tuberculosis in Nonhuman Primates

Therapy of Tuberculosis in Mice by DNA Vaccination.

Efficient Tuberculosis Treatment in Mice Using Chemotherapy and Immunotherapy with the Combined DNA Vaccine Encoding Ag85B, MPT-64 and MPT-83

Immunotherapeutic Efficacy of Recombinantmycobacterium Smegmatisexpressing Ag85B–ESAT6 Fusion Protein Against Persistent Tuberculosis Infection in Mice

Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan

Gls/Il-12-Modified Mycobacterium Smegmatis As A Novel Anti-Tuberculosis Immunotherapeutic Vaccine

Immunotherapeutics for Tuberculosis in Experimental Animals: is There A Common Pathway Activated by Effective Protocols?

Antibody-Fab and -Fc features promote Mycobacterium tuberculosis restriction.

Antibodies as key mediators of protection against Mycobacterium tuberculosis

Immunogenicity and Protective Efficacy of a Multi-Antigen Mycobacterium tuberculosis Subunit Vaccine in Mice

Therapeutic Efficacy of High-Dose Intravenous Immunoglobulin Inmycobacterium Tuberculosisinfection in Mice

Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis

Immunization of Vγ2Vδ2 T Cells Programs Sustained Effector Memory Responses That Control Tuberculosis in Nonhuman Primates.

Author Correction: an Anti-Lpqh Human Monoclonal Antibody from an Asymptomatic Individual Mediates Protection Against Mycobacterium Tuberculosis

Synergistic role of Mycobacterium indicus pranii and Human Beta Defensin-2 as adjunctive therapy against Mycobacterium tuberculosis

Intravenous Immunization with Triple Auxotrophs of : A novel vaccine strategy against tuberculosis